Industry Pulse
Peptide research news, regulatory developments, and industry analysis.
Latest Coverage
FDA Reverses Course on Seven Peptides: PCAC Reviews BPC-157, TB-500, KPV in July
The FDA Pharmacy Compounding Advisory Committee will convene July 23-24, 2026 to consider adding BPC-157, TB-500, KPV, Semax, Epitalon and others to the 503A bulks list. The proposed expansion runs opposite to the May 1 restriction on compounded GLP-1 peptides.
What “Research Use Only” Actually Means: The Legal Distinction Researchers and Buyers Keep Conflating
Research use only peptides occupy a narrow legal category that buyers and sellers increasingly treat as a generic disclaimer. As FDA enforcement intensifies in 2026, the RUO line is becoming the dividing line between legitimate laboratory commerce and federal regulatory exposure.
The Peptide Wild West Hits Mainstream Media: What the Coverage Misses About Research Suppliers
Major outlets including Fox News, CBS, The Hill, and Medscape ran “peptide wild west” coverage in the past week. The framing flattens distinctions between research suppliers, compounding pharmacies, and gray-market injectables.
FDA Moves to Ban Compounded Semaglutide and Tirzepatide: What Researchers Need to Know
On May 1, 2026, the FDA filed a proposal that would effectively end large-scale compounding pharmacy access to semaglutide and tirzepatide. Coverage of what the proposal contains and what it means for laboratory research suppliers.
Beyond Ozempic and Mounjaro: A Five-Target Obesity Drug Just Outperformed Both
A research team at Helmholtz Zentrum München has published the design of a single-molecule quintuple agonist that activates GLP-1, GIP, and three PPAR receptor subtypes. Published in Nature on April 28, 2026.